Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Phase 3
Completed
Conditions
First Posted Date
2004-03-12
Last Posted Date
2013-12-04
Lead Sponsor
Medical Research Council
Target Recruit Count
800
Registration Number
NCT00003421
Locations
🇬🇧

Weston Park Hospital, Sheffield, England, United Kingdom

🇬🇧

St. James's Hospital, Leeds, England, United Kingdom

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 3
Conditions
First Posted Date
2004-03-12
Last Posted Date
2009-02-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
280
Registration Number
NCT00002858
Locations
🇫🇷

Institut Claudius Regaud, Toulouse, France

🇫🇷

Hopital Haut Leveque, Pessac, France

🇫🇷

CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France

and more 16 locations

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Phase 3
Completed
Conditions
First Posted Date
2004-03-11
Last Posted Date
2013-03-28
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
3300
Registration Number
NCT00002823
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇸🇮

University of Ljubljana, Ljubljana, Slovenia

and more 120 locations

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

First Posted Date
2004-03-11
Last Posted Date
2010-10-01
Lead Sponsor
Temple University
Registration Number
NCT00002508
Locations
🇺🇸

Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

First Posted Date
2004-03-09
Last Posted Date
2014-05-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT00079040
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

First Posted Date
2004-03-09
Last Posted Date
2017-03-30
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
175
Registration Number
NCT00079105
Locations
🇬🇧

Royal United Hospital, Bath, England, United Kingdom

🇬🇧

Kent and Canterbury Hospital, Canterbury, England, United Kingdom

🇬🇧

Saint Richards Hospital, Chichester, England, United Kingdom

and more 51 locations

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

First Posted Date
2004-03-09
Last Posted Date
2015-05-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1
Registration Number
NCT00078988
Locations
🇺🇸

Children's Hospital and Health Center - San Diego, San Diego, California, United States

🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States

and more 56 locations

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

First Posted Date
2004-03-05
Last Posted Date
2019-10-17
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT00005946
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
First Posted Date
2004-03-03
Last Posted Date
2012-06-12
Lead Sponsor
Northwestern University
Target Recruit Count
6
Registration Number
NCT00004898
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath